Dow Jones received a payment from EQS/DGAP to publish this press release.
EQS-News / 22/11/2017 / 16:54 UTC+8
*Shineway's exclusive product Huamoyan Granule* *recorded sales surge of
33%*
(Hong Kong, 22 November 2017) ---- The largest Chinese medicine injections,
soft capsules and granules manufacturer in PRC, *China Shineway
Pharmaceutical Group Limited*, and collectively with its subsidiaries
("China Shineway") (SEHK stock code: 2877) today told investors in a monthly
newsflash the following:
1. Shineway's exclusive product, Huamoyan Granule, recorded sales surge of
33% for the first 10 months of 2017. Huamoyan Granule, as the first
innovative drug in China for specialized treatment of synovitis, has won a
number of national patents and entered into the latest national
reimbursement drug list in 2017.
2. At present, Shineway is actively involved in formulating the national
standards of Chinese medicine prescription granule to drive its
standardization. Furthermore, the "Hebei Province Chinese Medicine
Prescription Granules Engineering Technology Research Centre" jointly
established by Shineway and Hebei University of Chinese Medicine also serves
as cornerstone for innovative research and quality assurance on Chinese
medicine prescription granule.
3. In October 2017, the State Council promulgated the "Opinions on Deepening
the Reform of Examination and Approval System to Encourage the Innovation of
Medicines and Medical Devices". The Opinions stipulates injection products
on the market be subject to re-evaluation, and specifies that those which
passed the re-evaluation would enjoy relevant encouragement policies
available to generic drugs with proven consistency on quality and efficacy.
A few years ago, Shineway has already taken the lead by corroborating with
Tsinghua University to carry out researches on the substance base and
re-evaluation on the safety of Chinese medicine injections. Currently, the
work on substance base and escalation on quality assurance standards of all
Shineway's Chinese medicine injection products have been completed. In
addition, the three major Chinese medicine injection products of Shineway
(Qing Kai Ling Injection, Shen Mai Injection and Shu Xie Ning Injection)
have each completed 30,000 cases of evidence based clinical studies on their
safety, leading to more in-depth clinical evidence to support for rational
use of these medicines. Evidence-based medical researches on Shineway's
other Chinese medicine injection products are also underway.
End
*About China Shineway Pharmaceutical Group Limited (Stock Code: 2877)*
China Shineway Pharmaceutical Group Limited is one of the largest modern
Chinese medicines manufacturers in the PRC. The Group is listed on the Main
Board of Hong Kong Stock Exchange and is also a Hang Seng Composite Index
constituent.
Media Contact:
China Shineway Pharmaceutical Group Limited
Mr. Randy Hung ¦ Tel: (852) 3521-0816 ¦ randyhung@shineway.com.hk
Document: http://n.eqs.com/c/fncls.ssp?u=WRLKWFCSEJ [1]
Document title: Shineway's exclusive product Huamoyan Granule recorded sales
surge of 33%
22/11/2017 Dissemination of a Marketing Press Release, transmitted by EQS
Group.
The issuer is solely responsible for the content of this announcement.
Media archive at www.todayir.com
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=98b015e66de270742de31af389eecd05&application_id=631719&site_id=vwd&application_name=news
(END) Dow Jones Newswires
November 22, 2017 03:56 ET (08:56 GMT)
